Table of Contents
In nephrology, traditional “hard” endpoints such as progression to end-stage renal disease or death can take decades to occur, making clinical trials essential for accelerating studies and helping teams make critical decisions faster and with more information. Yet the full possibilities in this field have barely been tapped.
The Early Evolution of Nephrology Biomarkers Clinical Trials
The early stages of nephrology’s biomarker journey were mostly defined by serum creatinine and proteinuria data used to characterize disease severity and monitor patient progression. In the late 1990s, doubling of serum creatinine was established as a surrogate endpoint for kidney failure. However, with this occurring very late in disease, renal trials continued to be long and costly.
How Albuminuria Became a Prognostic Tool
In the 1990s and 2000s, large diabetic nephropathy studies such as the RENAAL trial showed that large early reductions in albuminuria shortly after RAAS blockade strongly predicted lower risk of progressing to end-stage renal disease. With this, markers such as albuminuria and proteinuria evolved into prognostic tools within clinical trials, allowing researchers to enroll patients with macroalbuminuria under the expectation they would progress faster and generate more renal events, improving trial efficiency through enriched populations.
A Major Turning Point for Nephrology Biomarkers Clinical Trials
Analysis also entered into dose selection, allowing investigators to compare doses based on albuminuria lowering. At the same time, these assessments began informing go/no-go decisions on an increasing basis, enabling sponsors to answer important questions, such as whether the drug is hitting the correct pathway, earlier in development.
FDA Acceptance of eGFR as a Surrogate Endpoint
A major turning point came in the early 2010s, when the FDA began to accept estimated glomerular filtration rate signals as surrogate endpoints, such as a greater than 40% decline in eGFR. This enabled earlier readouts, smaller studies, and accelerated development timelines within nephrology biomarkers clinical trials. Since then, eGFR endpoints have continued to progress, with some applications now considering a 30% decline for approval, while researchers commonly analyze the rate of kidney function decline using eGFR slopes, which may now be accepted as a valid primary endpoint by the FDA and EMA.
Why eGFR Endpoints Matter for Rare Kidney Diseases
Compared to waiting for a distant, fixed event such as serum creatinine doubling or end-stage renal disease, eGFR endpoints have made research in earlier-stage kidney disease increasingly possible. These milestones have been especially important in rare diseases, where biotechs are likely to experience particularly challenging enrollment and prohibitively expensive pediatric-to-adult follow-up periods.
Under the accelerated approval framework, orphan drugs such as Tarpeyo and Filspari, the first disease-specific therapies approved for IgA nephropathy and focal segmental glomerulosclerosis respectively, became available based on proteinuria and eGFR-based evidence, demonstrating the real-world regulatory impact of clinical trials methodology.
A major turning point came in the early 2010s, when the FDA began to accept kidney.org/professionals/gfr”>estimated glomerular filtration rate signals as surrogate endpoints, such as a greater than 40% decline in eGFR. This enabled earlier readouts, smaller studies, and accelerated development timelines. Since then, eGFR endpoints have continued to progress, with some applications now considering a 30% decline for approval, while researchers commonly analyze the rate of kidney function decline using eGFR slopes, which may now be accepted as a valid primary endpoint by the FDA and EMA.
Mechanistic Biomarkers Expanding Nephrology Biomarkers Clinical Trials
Today, possibilities continue to expand. In recent years, investigators have been exploring an alternative subset of markers that could provide valuable insight into unique aspects of kidney tubule health. New markers such as Kidney Injury Marker-1 and neutrophil gelatinase-associated lipocalin enable researchers to quantify the severity of tubule cell injury, now increasingly recognized as a central aspect of chronic kidney disease progression.
Why These New Markers Matter Even Before Regulatory Validation
Although new mechanistic markers such as KIM-1 and NGAL are still exploratory from a regulatory standpoint, they can already help biotechs enhance the value proposition of their assets through better understanding of a drug’s mechanism of action, potentially giving commercial leadership teams and investors the confidence needed to expand populations, add new labels, and explore differentiated clinical positioning.
Biomarker Panels and AI’s Growing Role in Nephrology Biomarkers Clinical Trials
Research has demonstrated that kidney disease is highly heterogeneous, with multiple different pathways altering kidney function and structure, from inflammation and fibrosis to tubular injury, glomerular damage, and immune activation. A single marker is unable to capture this complexity alone, especially since those in wide use today, like eGFR and albuminuria, are generic indicators of glomerular filtration and damage.
Combining Signals Across Multiple Pathways
Panels combine signals from multiple pathways, such as eGFR and proteinuria for filtration function, KIM-1 for tubular injury, TNFR1/2 for inflammation, and suPAR for immune activation. This improves accuracy and mitigates the limitations of individual markers. As the use of AI grows in clinical trials, there is increasing potential for machine learning and AI-based predictive modeling techniques to enter the picture, with new algorithms analyzing data across multiple markers and patient information sources to predict a patient’s risk score for progressive kidney function decline.
Toward Precision Medicine in Nephrology Biomarkers Clinical Trials
With greater understanding of the many different underlying biological pathways that drive kidney disease, there is potential to shift from prognostic indicators toward predictive ones. By identifying pathway-specific responders through predictive markers, sponsors have the potential to advance drugs that would otherwise appear ineffective in heterogeneous populations.
An Approach Already Proven in Oncology
In one potential example, elevated chronic inflammation biomarkers such as TNFR-1 or TNFR-2 could be used to identify a subgroup of patients who may respond well to anti-inflammatory drugs, a method already seeing significant success in oncology but relatively untapped in nephrology, with the potential to improve patient outcomes through tailored treatments.
Maximizing the Opportunities in Nephrology Biomarkers Clinical Trials
As the possibilities of biomarkers in nephrology continue to strengthen, selecting the right signals and successfully integrating them within protocols and endpoints becomes critical, especially given the potential to accelerate trials and differentiate assets from competition.
What Sponsors Need to Succeed
To realize these possibilities, sponsors require strategic input and guidance from a high-touch CRO partner with deep expertise in the therapy area and strong understanding of kidney disease nuances, helping harness the latest trends in clinical trials to accelerate studies, enhance patient selection, and guide clinical strategies that bring innovative treatments to patients faster.
For more healthcare industry updates, insights and news, visit DistilINFO. Click here to subscribe to stay informed.
